In Oct 2007, the FDA declared that the labeling for all PDE5 inhibitors, which include tadalafil, needs a additional distinguished warning on the likely threat of sudden hearing reduction as the result of post-marketing and advertising experiences of short-term deafness linked to utilization of PDE5 inhibitors.[19]Some study indicates the backlink